Table 4. Analysis of Secondary Outcome Complications From Baseline to 6 Months by Allocated Treatment Group.
| Characteristics by follow-up period | No. (%)a | |
|---|---|---|
| Platelet-rich plasma | Sham | |
| 2 wk | ||
| No. | 119 | 119 |
| Bleeding at injection site | 24 (20.2) | 36 (30.3) |
| Bruising at injection site | 48 (40.3) | 49 (41.2) |
| Fainting | 0 | 0 |
| Infection at injection site | 0 | 0 |
| Mild discomfort at injection site | 97 (81.5) | 73 (61.3) |
| Swelling at injection site | 56 (47.1) | 52 (43.7) |
| Skin discoloration at injection site | 24 (20.2) | 22 (18.5) |
| Allergic reaction | 0 | 1 (0.8) |
| Otherb | 8 (6.7) | 6 (5.0) |
| 3 mo | ||
| No. | 116 | 110 |
| Bleeding at injection site | 0 | 0 |
| Bruising at injection site | 4 (3.4) | 7 (6.4) |
| Fainting | 0 | 0 |
| Infection at injection site | 0 | 0 |
| Mild discomfort at injection site | 20 (17.2) | 15 (13.6) |
| Swelling at injection site | 11 (9.5) | 11 (10.0) |
| Skin discoloration at injection site | 4 (3.4) | 0 |
| Allergic reaction | 0 | 0 |
| Otherb | 4 (3.4) | 3 (2.7) |
| 6 mo | ||
| No. | 110 | 111 |
| Bleeding at injection site | 0 | 0 |
| Bruising at injection site | 0 | 1 (0.9) |
| Fainting | 0 | 0 |
| Infection at injection site | 0 | 0 |
| Mild discomfort at injection site | 9 (8.2) | 1 (0.9) |
| Swelling at injection site | 3 (2.7) | 5 (4.5) |
| Skin discoloration at injection site | 0 | 0 |
| Allergic reaction | 0 | 0 |
| Otherb | 1 (0.9) | 2 (1.8) |
a
Numeric values indicate complications reported at least once per participant; percentages exclude unknown answers at each follow-up.
b
Category included episodes of cramping, ankle stiffness, numbness, nausea, temporary visual disturbance, and swelling behind the knee.